BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37424676)

  • 1. Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide.
    Zhang L; Liu H; Zou Z; Su S; Ong JJ; Ji F; Cui F; Chan PL; Ning Q; Li R; Shen M; Fairley CK; Liu L; Seto WK; Wong WCW
    Lancet Reg Health West Pac; 2023 Jun; 35():100737. PubMed ID: 37424676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.
    Zhang S; Wang C; Liu B; Lu QB; Shang J; Zhou Y; Jia J; Xu X; Rao H; Han B; Zhao T; Chen L; Xie M; Cui J; Du J; Zeng J; Huang N; Liu Y; Zhang L; Zhuang H; Cui F
    Lancet Reg Health West Pac; 2023 Jun; 35():100738. PubMed ID: 37424693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.
    Goyal A; Murray JM
    Clin Drug Investig; 2016 Aug; 36(8):637-48. PubMed ID: 27166628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea.
    Lee D; Shin HY; Park SM
    Cost Eff Resour Alloc; 2018; 16():6. PubMed ID: 29467596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population impact and cost-effectiveness of artificial intelligence-based diabetic retinopathy screening in people living with diabetes in Australia: a cost effectiveness analysis.
    Hu W; Joseph S; Li R; Woods E; Sun J; Shen M; Jan CL; Zhu Z; He M; Zhang L
    EClinicalMedicine; 2024 Jan; 67():102387. PubMed ID: 38314061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model.
    Jing W; Liu J; Wu Y; Ma Q; Liu M
    EClinicalMedicine; 2020 Feb; 19():100264. PubMed ID: 32055793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.
    Xie L; Yin J; Xia R; Zhuang G
    Hepatology; 2018 Oct; 68(4):1476-1486. PubMed ID: 29633304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
    Dai Z; Wong IOL; Xie C; Xu W; Xiang Y; Peng L; Lau EHY
    Clin Microbiol Infect; 2022 Feb; 28(2):300.e1-300.e8. PubMed ID: 34197929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the national hepatitis B immunization program in China: a modeling study.
    Liu Z; Li M; Hutton DW; Wagner AL; Yao Y; Zhu W; Cao L; Tang S; Pan J; Wang Y; Zhao Q; Ren H; Wang Y; Wang W
    Infect Dis Poverty; 2022 Oct; 11(1):106. PubMed ID: 36221140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.
    Zeng Y; Luo M; Lin J; He H; Deng X; Xie S; Fang Y
    Hum Vaccin Immunother; 2020 Apr; 16(4):955-964. PubMed ID: 31769718
    [No Abstract]   [Full Text] [Related]  

  • 15. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia.
    Toy M; Hutton D; McCulloch K; Romero N; Revill PA; Penicaud MC; So S; Cowie BC
    Liver Int; 2022 Jan; 42(1):16-25. PubMed ID: 34328697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
    Yuan Y; Iloeje U; Li H; Hay J; Yao GB
    Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
    Toy M; Hutton DW; So SK
    PLoS One; 2015; 10(11):e0139876. PubMed ID: 26536626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.